| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.42 | 2e-28 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.44 | 2e-26 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.35 | 1e-17 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.3 | 6e-17 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.27 | 3e-13 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.29 | 2e-12 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.29 | 2e-12 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.38 | 3e-12 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.26 | 4e-12 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | 0.28 | 1e-11 |